Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 13/20 | 1.00 |
| ▸ | NR0B2 | Q15466 | 4/20 | 1.00 |
| ▸ | RARB | P10826 | 3/20 | 0.74 |
| ▸ | PTPRCAP | Q14761 | 2/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.58 |
| ▸ | RARA | P10276 | 1/20 | 0.55 |
| ▸ | RARG | P13631 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1914213 | 1.00 | PTPN11 (1.00) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL1914215 | 1.00 | PTPN11 (1.00) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL12257833 | 0.91 | PTPN11 (0.83) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL2389152 | 0.89 | RARB (0.80) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL2389155 | 0.89 | RARB (0.80) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL3289754 | 0.89 | PTPN11 (0.80) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL3289761 | 0.89 | PTPN11 (0.80) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL2391213 | 0.87 | PTPN11 (0.77) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL2391204 | 0.87 | PTPN11 (0.77) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL2407028 | 0.87 | PTPN11 (0.77) | PTPN11NR0B2RARBPTPRCAPHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024176130-A1 | TEAD- AND HER2-INHIBITOR COMBINATIONS FOR TREATING CANCER | NOVARTIS AG (CH) | 2024-08-29 | — | — | WO | claimed |
| WO-2024176131-A1 | TEAD- AND KRAS G12D-INHIBITOR COMBINATIONS FOR TREATING CANCER | NOVARTIS AG (CH) | 2024-08-29 | — | — | WO | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024176130-A1 | TEAD- AND HER2-INHIBITOR COMBINATIONS FOR TREATING CANCER | NOVARTIS AG (CH) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024176131-A1 | TEAD- AND KRAS G12D-INHIBITOR COMBINATIONS FOR TREATING CANCER | NOVARTIS AG (CH) | 2024-08-29 | — | — | WO | disclosed |
| EP-3519383-B1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | BIOGEM S C A R L (IT) | 2024-08-21 | — | — | EP | disclosed |
| US-11819484-B2 | Retinoid derivatives with antitumor activity | BIOGEM S.C. A R.L. (IT) | 2023-11-21 | — | — | US | disclosed |
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022229017-A1 | ADAMANTYL RETINOID DERIVATIVE WITH ANTICANCER ACTIVITY | BIOGEM S.C.A R.L. (IT) | 2022-11-03 | — | — | WO | disclosed |
| CN-110114338-B | Retinoid derivatives having antitumor activity | 比奥吉公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-4074695-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2022-10-19 | — | — | EP | disclosed |
| US-11364216-B2 | Retinoid derivatives with antitumor activity | BIOGEM S.C. A R.L. (IT) | 2022-06-21 | — | — | US | disclosed |
| US-20220168252-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | BIOGEM S C A R L (IT) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168252-A1 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | RARA, RARB, RARG | PTPN11 1866/4885NR0B2 33/4885RARB 2/4885 |
| US-11819484-B2 | Retinoid derivatives with antitumor activity | RARA, RARB, RARG | PTPN11 1866/4885NR0B2 33/4885RARB 2/4885 |
| US-11364216-B2 | Retinoid derivatives with antitumor activity | RARA, RARB, RARG | PTPN11 1866/4885NR0B2 33/4885RARB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.